1. Pancreatic cancer prognosis
2. NSD1 expression in cancer
3. SETD2 alteration pancreatic cancer
4. Epigenetic regulation in PDA
5. Histone methylation cancer research

New research delves into the molecular intricacies of pancreatic ductal adenocarcinoma (PDA), unearthing significant revelations about the expression and prognostic value of specific genes that are foundational to our understanding of the disease’s progression and offering new avenues for diagnosis and treatment strategies.

At the forefront of this research is the study led by Mark M. Ettel et al., titled “Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions,” providing an insightful analysis into two epigenetic regulators, NSD1 and SETD2. Published in “Pathology,” this groundbreaking study is accessible through the digital object identifier (DOI): 10.1016/j.pathol.2019.02.005.

Background of Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma, a devastatingly aggressive form of cancer, remains a substantial health challenge with an urgent need for more effective diagnostic and prognostic biomarkers. It represents one of the most lethal malignancies, with very few patients surviving beyond five years post-diagnosis. Recent years have seen an increasing focus on the role of epigenetic modifications in cancer development, with histone methylation recognized as a critical mechanism impacting gene expression and subsequent cellular behavior.

NSD1 and SETD2: Critical Players in the Epigenetic Landscape of Cancer

The NSD1 and SETD2 genes encode histone H3K36 methyltransferases – enzymes responsible for the methylation of specific lysine residues on histone proteins. This histone modification is crucial for regulating the structure of chromatin and, thus, the accessibility of genes for transcription. The research underscores the importance of these genes by highlighting mutations or alterations in them in approximately 8-10% of PDA cases. However, until the study by Ettel et al., the specifics of how NSD1 and SETD2 protein expression is altered in PDA and its precursors, and their potential diagnostic or prognostic utility, remained unclear.

Methodology and Findings: A Deep Dive into Expression Patterns

The study employed the use of tissue microarrays, composed of cases of PDA, metastatic PDA, various precursor lesions like pancreatic intraepithelial neoplasia (PanIN), and benign pancreatic tissues to qualitatively assess the expression of NSD1 and SETD2 by immunohistochemistry. This examination method allowed for the determination of both the intensity and percentage of positive cells within the samples.

What emerged from the investigation were clear patterns in protein expression. NSD1 expression was significantly increased in metastatic PDA compared to benign ducts, primary PDA, and other lesions. In contrast, SETD2 protein expression saw a significant decrease in metastatic PDA and PanIN lesions compared with benign counterparts.

Implications and Prognostic Considerations

These expression patterns are revealing in more than just the biological progression of the disease; they have tangible implications for patient outcomes. High NSD1 expression correlated with more advanced clinical stages of PDA, indicating its potential as a marker for aggressive disease. Patients with elevated levels of NSD1 often faced stage III/IV disease, higher tumor grades, and were typically recipients of neoadjuvant therapy – a treatment given to shrink the tumor before the main treatment. Intriguingly, despite these correlations, there was no significant difference observed in overall and progression-free survival rates based on NSD1/SETD2 expression levels.

Increased NSD1: A Target for Therapeutic Intervention?

Given these insights, NSD1 emerges as a candidate for further exploration as a prognostic marker – its increase in expression is significantly associated with more severe disease criteria. However, its direct role in therapy or its potential to guide treatment remains to be comprehensively understood. The lack of survival rate differences suggests that while NSD1 is indicative of disease severity, it doesn’t necessarily predict patient outcomes, thereby introducing the prospect that it could be more effectively used in conjunction with other markers or targeted therapies.

The Role of SETD2: A Diagnostic Potential?

On the other hand, SETD2, with its decreased expression identified in early precursor lesions such as PanIN, could serve as a red flag for the development of PDA. This finding points to its potential utility in diagnosing the disease perhaps before it fully manifests, although the intricacies of this possibility will require further probing.

Moving Forward in Pancreatic Cancer Research

By closing the gap in our knowledge concerning these two vital epigenetic players, the study represents a meaningful advancement in the quest to combat PDA. The diagnostic and prognostic revelations not only offer a broader understanding but also pave the way for the strategic targeting of specific genetic anomalies observed in cancer progression.

Impacts and Outlook

Research into the epigenetic underpinnings of PDA can redefine the therapeutic landscape, providing a precision medicine approach that could selectively target aberrant histone modifications caused by NSD1 and SETD2 mutations or alterations. This direction is supported by the plethora of studies linking histone methylation to various cancers, suggesting a more significant epigenetic pattern underlying malignancies beyond PDA.

Limitations and Future Studies

While the study by Ettel et al. represents a substantial leap forward, it also underscores the necessity for more extensive research to exploit the full prognostic and therapeutic potential of NSD1 and SETD2. Future investigation may well benefit from the inclusion of larger cohort studies, longitudinal analyses, and deeper genomic sequencing to validate the findings and extend its applications.


Pancreatic ductal adenocarcinoma remains a challenging adversary in the field of oncology, but research like that of Ettel et al. equips us with the incisive scientific insight necessary to combat it more effectively. With better understanding of the roles that histone-modifying genes play in the development and progression of PDA, it’s a hopeful step towards improved diagnostic, prognostic, and treatment strategies that can one day turn the tide in the fight against this formidable cancer.


1. Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 74(11), 2913-2921. Doi: 10.1158/0008-5472.CAN-14-0155

2. Silverman, B. R., & Shi, J. (2016). Alterations of epigenetic regulators in pancreatic cancer and their clinical implications. Int J Mol Sci, 17(12), E2138. Doi: 10.3390/ijms17122138

3. Waddell, N., Pajic, M., Patch, A. M., et al. (2015). Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), 495–501. Doi: 10.1038/nature14169

4. Witkiewicz, A. K., McMillan, E. A., Balaji, U., et al. (2015). Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun, 6, 6744. Doi: 10.1038/ncomms7744

5. Ettel, M. M., Zhao, L., Schechter, S., & Shi, J. (2019). Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. Pathology, 51(4), 392–398. Doi: 10.1016/j.pathol.2019.02.005